27 May 2025 Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions].

Mesoblast Ltd (ASX: MSB) shares could still be relatively cheap despite doubling in value according to one leading ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

The District Court for the District of Delaware recently rejected Novartis’s effort to block MSN Pharmaceuticals from launching a generic version ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis could soon face generic competition for Entresto after judge's ruling.

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to an 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...